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Abstract  
 Cysteine protease inhibitors have long been part of drug discovery 
programs for Alzheimer's disease (AD), traumatic brain injury (TBI), and 
other disorders. Select inhibitors reduce accumulating proteins and AD 
pathology in mouse models. One such compound, Z-Phe-Ala-
diazomethylketone (PADK), exhibits a very weak IC50 (9-11 μM) towards 
cathepsin B (CatB), but curiously PADK causes marked up-regulation of the 
Aβ-degrading CatB and improves spatial memory. Potential therapeutic and 
weak inhibitor E64d (14 μM IC50) also up-regulates CatB. PADK and E64d 
were compared regarding the blockage of calcium-induced cytoskeletal 
deterioration in brain samples, monitoring the 150-kDa spectrin breakdown 
product (SBDP) known to be produced by calpain. PADK had little to no 
effect on SBDP production at 10-100 μM. In contrast, E64d caused a dose-
dependent decline in SBDP levels with an IC50 of 3-6 μM, closely matching 
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its reported potency for inhibiting μ-calpain. Calpain also cleaves the 
cytoskeletal organizing protein gephyrin, producing 49-kDa (GnBDP49) and 
18-kDa (GnBDP18) breakdown products. PADK had no apparent effect on 
calcium-induced gephyrin fragments whereas E64d blocked their production. 
E64d also protected the parent gephyrin in correspondence with reduced BDP 
levels. The findings of this study indicate that PADK’s positive and selective 
effects on CatB are consistent with human studies showing exercise elevates 
CatB and such elevation correlates with improved memory. On the other hand, 
E64d exhibits both marginal CatB enhancement and potent calpain inhibition. 
This dual effect may be beneficial for treating AD. Alternatively, the potent 
action on calpain-related pathology may explain E64d’s protection in AD and 
TBI models. 
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Introduction 
 The age-related protein accumulation disorder Alzheimer’s disease 
(AD) afflicts more than 5 million people in the U.S., also causing stress to 
caregivers, family, and friends. Furthermore, the disease greatly burdens a 
healthcare system that is incurring over $250 billion in costs each year. The 
process of aging is known to exacerbate pathogenic protein accumulation, as 
most non-familial cases of AD occur in people 65 years or older. Features of 
AD include i) intracellular aggregates, ii) extracellular deposits, and iii) 
multiproteinopathic components comprising of Aβ42, amyloid precursor 
protein (APP) fragments, hyperphosphorylated tau, and often TDP-43 and α-
synuclein (Nixon, 2007; Mazzuli et al., 2016). Protein accumulations occur 
prior to the onset of synaptic pathology and neurodegeneration (Bendiske et 
al., 2002; Goldberg, 2003; Butler et al., 2005), likely as a result of an 
imbalance between protein synthesis and degradation.  
 Lysosomes contain a variety of cysteine, aspartyl, and serine proteases 
as well as other enzymes as part of a key protein degradation pathway. 
Cathepsins are among the proteolytic enzymes located within the acidic 
environment of the lysosome where their main function is the degradation of 
large biomolecules (see Bahr, 2009; Ditaranto et al., 2001; Wang et al., 2017). 
The specific enzyme cathepsin B (CatB) has been implicated as a therapeutic 
target for AD since it degrades Aβ42 into less pathogenic peptides through C-
terminal truncation (Mueller-Steiner et al., 2006; Butler et al., 2011). In 
addition, positive CatB modulation appears to be a cellular protection avenue 
since the enzyme exhibits an enhancement effect in response to many types of 
protein clearance compromise and protein accumulations, including:  
 Proteasome inhibitor treatment in SH-SY5Y cells (Cecarini et al., 
2014) 
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 Proteasome inhibition in SH-SY5Y cells expressing human APP 
(Cecarini et al., 2014) 
 Intrahippocampal injection of proteasome inhibitor in aged rats 
(Gavilán et al., 2015) 
 Proteasome inhibitor treatment in hippocampal slices (Farizatto et al., 
2017) 
 Chloroquine-induced lysosomal stress in hippocampus (Bendiske & 
Bahr, 2003). 
 High concentration Aβ42 in hippocampal slices (Bendiske & Bahr, 
2003) 
 Low-levels of Aβ42 in hippocampal slices (Farizatto et al., 2017) 
 Aβ42 treatment of a mouse neuronal cell line (Mueller-Steiner et al., 
2006) 
 Expression of mutant human APP in mouse brain (Mueller-Steiner et 
al., 2006) 
 Human huntingtin expression in cultured neurons (Wu et al., 2012) 
  
 Note that a compensatory inter-relationship between the proteasomal 
and lysosomal protein clearance pathways has been suggested with recent 
evidence showing that impairment of the proteasomal system activates CatB 
and the lysosomal system (Cecarini et al., 2012; Farizatto et al., 2017). In 
addition, a positive modulator of the lysosomal system enhanced the level of 
CatB activity and also reduced Aβ accumulation in neuroblastoma cells 
expressing mutant APP (Park et al., 2016). Across AD transgenic mouse 
models, genetic and pharmacological manipulations found to increase CatB 
activity also reduced Aβ levels and offset disease parameters (Mueller-Steiner 
et al., 2006; Sun et al., 2008; Butler et al., 2011; Yang et al., 2011; Wang et 
al., 2012). 
 In other studies, CatB inhibition has been linked to the reduction of Aβ 
deposits and improved memory in AD mouse models using the broad cysteine 
protease inhibitor E64d (see Hook et al., 2007, 2011, 2014a). E64d, however, 
was also found to potently inhibit the calcium-activated protease calpain and 
such inhibition was found to protect against different neuropathologies 
(Inubushi et al., 1994; Tsubokawa et al., 2006; Trinchese et al., 2008; Jeon et 
al., 2016). Thus, the current study compared the distinct compounds PADK 
and E64d with regard to the extent of their CatB modulation vs. their calpain 
blocking capacity. The latter was assessed by measuring calcium-dependent 
breakdown of the cytoskeletal protein spectrin that is implicated in many 
pathological states (Vanderklish & Bahr, 2000; Pineda et al., 2004; Weiss et 
al., 2009; Ono et al., 2016) and the calcium-dependent breakdown of gephyrin, 
a postsynaptic scaffold protein that recruits transmitter receptors and interacts 
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with a guanine nucleotide exchange factor (Kawasaki et al., 1997; Fekete et 
al., 2017).   
 
Materials and Methods  
 Hippocampal Slice Cultures. All studies with animals were carried out 
in accordance with the recommendations from the Guide for the Care and Use 
of Laboratory Animals from the National Institutes of Health. Brain tissue 
from postnatal 12-day-old Sprague-Dawley rats (Charles River Laboratories) 
was rapidly removed to prepare hippocampal slices (Farizatto et al., 2017; 
Butler et al., 2011). Transverse slices (400 μm) were quickly prepared and 
gently positioned on Millicell-CM inserts (Millipore, Billerica, 
Massachusetts). The hippocampal slices were maintained at 37°C in 5% CO2-
enriched atmosphere for 18-22 days before being treated with different agents. 
 Culture Treatments. E64d (2S,3S-trans-epoxysuccinyl-L-
leucylamido-3-methylbutane ethyl ester or aloxistatin; Sigma-Aldrich; St. 
Louis, Missouri) was applied daily to hippocampal slice cultures for 2-3 days. 
The compound Z-Phe-Ala-diazomethylketone (PADK; Bachem Inc., 
Torrance, California), which promotes mature CatB levels in different model 
systems (Ryzhikov & Bahr, 2008; Butler et al., 2011; Bahr et al., 2012) was 
similarly assessed in the hippocampal cultures. After treatments, cultured 
slices were gently removed from the inserts into groups of 7-9 each using ice-
cold isosmotic buffer and homogenates were prepared. 
 Cathepsin B Activity. The InnoZyme Assay Kit (Millipore) was used 
to measure CatB activity in the hippocampal slice samples treated with various 
concentrations of compounds. Aliquots of homogenized samples (10 μg 
protein) were assessed in duplicate for proteolytic activity using the Z-Arg-
Arg AMC substrate and the SpectraMax M3 microplate reader.   
 Calcium-Dependent Calpain Assay. Brain tissue homogenates were 
rapidly prepared from adult rats, which were humanely sacrificed by 
isoflurane anesthesia and decapitation. Brains were cooled and removed from 
the skull and then placed in ice-cold homogenization buffer. The brains were 
immediately dissected and telencephalic tissue was collected, homogenized 
and assayed for protein content level. Equal protein aliquots were incubated 
with 6 mM CaCl2 at 37°C, in the absence or presence of potential protease 
inhibitors, and then assessed by immunoblot for proteolytic products.  
 Immunoblot Analysis. Immunoblot samples of adult brain tissue and 
hippocampal slice cultures were sonicated in cold lysis buffer (Sigma-Aldrich; 
St. Louis, Missouri). Protein content was determined and equal amounts of 
protein were denatured in sample buffer and separated on gradient gels for 
subsequent transfer to nitrocellulose. Blots were incubated in blocking 
solution containing 5% milk or BSA for 1 h. Primary antibody staining utilized 
antibodies against cathepsin B (1:100, Calbiochem), GluR1 (1:1000; 
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Millipore) and anti-αII spectrin (1:100, Santa Cruz), as well as against actin 
20-33 (1:500, Sigma)  and an antibody to gephyrin’s C-terminal (1:250) made 
against the sequence VELHKGEVVDVMVIGRL described in Kawasaki et 
al. (1997). Anti-IgG-alkaline phosphatase conjugates and anti-IgG-
horseradish peroxidase conjugates were used for the secondary antibody step, 
and antigen staining and image development involved the chemiluminescence 
protocols using the GE Amersham AI600RGB imager. Immunostained bands 
were scanned at high resolution to determine integrated optical density with 
BIOQUANT software (R & M Biometrics, Nashville, Tennessee).  
 Transgenic Mice Assessment. Transgenic and control mice were 
housed in vivarium facilities until the desired age. The APPSwInd J20 line mice 
(Jackson Laboratories) exhibit lower levels of Aβ deposits compared to the 
original line, and were used at 9–10 months of age. Genotype was confirmed 
by PCR. Mice were handled daily for 1 week and subsequently received daily 
i.p. injections of 20 mg/kg PADK. Control mice were injected with the 
corresponding volume of vehicle. Mice were handled and familiarized with 
the open field used for spatial memory. The APPSwInd mice and age-matched 
wild-type mice were mildly caloric-restricted and assessed for spatial memory 
in the hidden food cache test. A food reward was placed in one of two opaque 
cylinders in opposite corners of an open field. The food location was changed 
after each 3-trial training session over a 24-h period, and food retrieval time 
was compared across trials. 
 Statistical Analyses. Specific immunoreactivity values [(optical 
density – background) × area] for each antigen were quantitatively compared. 
Results were evaluated with unpaired t tests or analyses of variance (ANOVA) 
followed by post hoc tests using Prism software (GraphPad, San Diego, 
California). IC50 and EC50 values were determined using nonlinear regression.  
 
Results  
 Potential targets of the weak cysteine protease inhibitors PADK and 
E64d include the lysosomal system and the calcium-activated protease calpain 
(Fig. 1a). PADK was assessed for CatB inhibitory action in brain 
homogenates, resulting in a very weak IC
50
 value of 9-10 µM (Fig. 1b). In 
contrast, lower PADK concentrations elicited positive modulation of the 30-
kDa CatB active isoform (CatB-30) in hippocampal slice cultures (Fig. 1c), 
including concentrations that produced no or minimal inhibitory effects on the 
enzyme (see grey zones in Figs. 1b and 1c).  
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 PADK’s dose-dependent modulatory effect on CatB-30 in Figure 1c 
exhibited an EC50 of 2.8 µM, thus was >3-times more potent than its weak 
inhibitory potency to explain its enhancing effect on CatB activity previously 
reported (Butler et al., 2005, 2011; Farizatto et al., 2017). This modulator 
induced a 3-6-fold increase in CatB-30 as compared to levels found in 
untreated hippocampal slices, and its effect was blocked by the very potent 
CatB inhibitor CA074 (open triangle in Fig. 1c). Corresponding with this 
CatB-enhancing effect, PADK improved spatial memory in APPSwInd 
transgenic mice using a novel hidden food cache paradigm (Table 1). APPSwInd 
and age-matched wildtype mice were trained to find the location of food that 
was placed in one of two opaque cylinders positioned in different 
configurations for each test. Wildtype mice exhibited improved time to find 
Figure 1. Potential enzyme modulation avenues. PADK and E64d are protease 
inhibitors that potentially target calpain and/or lysosomal hydrolases (a). PADK was 
assessed for its effect on CatB activity (b), exhibiting an IC50 of 9-10 µM in brain 
homogenates. PADK at 1-8 μM (grey zone) produced little inhibition (red arrows), while 
the same concentrations enhanced the CatB-30 active isoform 3-5 fold (c; green arrows) 
in hippocampal slice cultures (EC50 = 2.8 µM).  GluR1 was unchanged in PADK-treated 
samples (+). In the presence of the CatB inhibitor CA074, 10 μM PADK was unable to 
have an effect on CatB-30 (*p<0.05).   
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the food reward after three trials (p<0.001), whereas APPSwInd mice showed no 
improvement after 3 trials (Table 1). PADK treatment at 20 mg/kg/day (i.p.) 
allowed the transgenic mice to improve their food location time (p=0.036), to 
a level comparable to the performance by wildtype controls. These results are 
similar to the previously correlated improvement of episodic memory in APP-
PS1 mice (Butler et al., 2011).  
 ____________________________________________________________ 
                                                seconds to find food cache (mean ± SEM):   
 
            trial               WT mice        APPSwInd mice 
            1                11.0 ± 2.5            12.3 ± 2.8 
       3 + veh        6.30 ± 1.2**          13.1 ± 2.6   
       3 + PADK                      –                           6.16 ± 2.7* 
  
 
Table 1. Spatial memory was improved in 9-10-month APPSwInd mice treated with PADK (20 
mg/kg/day ip for 9 days). APPSwInd mice and age-matched wild-type mice (WT) were mildly 
caloric-restricted and assessed with the hidden food cache test. A food reward was placed in 
one of two opaque cylinders in opposite corners of an open field. The food location was 
changed after each 3-trial training session, and food retrieval time was compared across trials. 
**p<0.001, t-test compared to trial 1; *p=0.036, Mann-Whitney test compared to APPSwInd 
trial 3 + vehicle.  
 
 The broad cysteine protease inhibitor E64d also has been implicated as 
a treatment avenue for AD (Hook et al., 2007, 2011, 2014a). While it has been 
suggested that E64d’s inhibitory effect on CatB is the underlying therapeutic 
action for offsetting AD pathology, this weak protease inhibitor was found to 
increase CatB-30 (Table 2). Note that the positive modulation of CatB by E64d 
was less pronounced than the enhancing effect produced by PADK (increase 
of 76% vs. 549%; p<0.001). Other weak cysteine protease inhibitors were also 
found to up-regulate active CatB to varying degrees, including i) SD1002, a 
non-peptidyl PADK analogue previously found to promote Aβ42 clearance 
(Viswanathan et al., 2012), ii) the polyphenol quercetin that, like PADK and 
E64d, exhibits very weak CatB inhibitory action (Ramalho et al., 2015), and 
iii) Cathepsin Inhibitor 1 (CATI-1, also known as Z-Phe-Gly-NHO-Bz), a 
broad inhibitor of papain and several cathepsins (Table 2). The potent CatB 
inhibitors CA074, CA074me, and E64 did not exhibit positive modulation of 
CatB-30. Table 2 also compared the listed 8 compounds for their inhibitory 
action on the calcium-activated cysteine protease calpain and, interestingly, 
E64d and the related E64 compound stand out as the most potent. 
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  very weak inhibitors           CatB-30, percent±SEM      IC50 for CatB, µM     IC50 for calpain, µM 
     vehicle control               100 ± 4.0   –                – 
  
  PADK              1 µM                   340 ± 38.7**                          9 – 11a                                              ≥100 (from Fig. 3d) 
              10 µM      649 ± 74.5***  
  
  E64d                    1 µM      115 ± 9.2                                   14b                       3 – 6 (from Fig. 3b) 
          10 µM     176 ± 12.5*** ###             0.04 - 4c 
   
  SD1002           10 µM      345 ± 13.3**                  >50d                 n.d. 
   
  quercetin           10 µM      198 ± 19.2**   8e                                    211f 
    
  CATI-1            10 µM      149 ± 14.3**             weak inhibitorg              >20h 
  
      potent inhibitors               CatB-30, percent±SEM           IC50 for CatB, µM                   IC50 for calpain, µM 
  CA074           0.3-1 µM          95 ± 11.9                 0.004b                                  >100b 
  CA074me      0.3-1 µM                   116 ± 9.2                                0.12a                n.d. 
     E64          1-2 µM      112 ± 7.5                 0.03i               0.57j 
   
 
Table 2. Comparisons among weak cysteine protease inhibitors and potent inhibitors 
regarding CatB-enhancing activity in hippocampal slice cultures and inhibitory activity 
targeting CatB and calpain. Measures of the 30-kDa CatB isoform (CatB-30) in treated 
hippocampal slices were from Farizatto et al. (2017). ANOVA multiple comparison tests 
compared to vehicle control: **p<0.01, ***p<0.001; unpaired t-test compared to 10 μM 
PADK: ###p<0.001. IC50 values for inhibiting calpain-mediated SBDP production are shown 
for PADK and E64d from Fig. 3. Other IC50 values for inhibiting CatB and calpain were 
obtained from the following references: a, Butler et al., 2011; b, Jeon et al., 2016; c, Huang et 
al., 1992; d, Viswanathan et al., 2012; e, Ramalho et al., 2015; f: Je Ma et al., 2009; g, 55; h, 
Montagne et al., 2017; i, Inubushi et al., 1994; j, Trinchese et al., 2008. CATI-1, Cathepsin 
Inhibitor 1; n.d., not determined.  
  
 To determine whether PADK and E64d have different actions on the 
calcium-activated calpain, assays were conducted to assess their ability to 
inhibit previously characterized breakdown products of spectrin and gephyrin 
mediated by calpain (SBDP and GnBDP; Fig. 2). Pathogenic calpain 
activation is known to cleave the α-subunit of the cytoskeletal protein spectrin 
(Vanderklish & Bahr, 2000). Calpain also cleaves the postsynaptic scaffold 
protein gephyrin into long-lasting fragments of 18 and 49 kDa (Kawasaki et 
al., 1997). Brain homogenates were prepared and incubated with calcium, 
producing a 150-kDa αII-spectrin fragment, and E64d inhibited this SBDP 
production (Fig. 3a). The dose-dependent inhibitory effect exhibited an IC50 
of 3-6 μM (ANOVA p=0.0066; Fig. 3b), closely matching E64d’s reported 
potency for blocking μ-calpain (Huang et al., 1992). PADK, on the other hand, 
did not decrease SBDP levels in calcium-treated brain samples (Fig. 3c). 
Insignificant variability in SBDP levels was found (Fig. 3d), but some calpain 
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inhibition may occur at very high PADK concentrations that would negate its 
positive modulation of CatB.  
 
Figure 2. Calpain-mediated proteolysis of spectrin and gephyrin. Compounds may have 
an effect on calpain, a calcium-activated protease that generates breakdown products of 
spectrin (SBDPs of 150-152 kDa) and gephyrin (GnBDPs of 18 and 49 kDa). 
   
Fig. 3. E64d blocks calcium-induced spectrin breakdown while PADK does not. Rat 
telencephalic homogenates were not treated (NT) or treated with CaCl2 at 37°C for 1 h to 
activate proteases in the presence of E64d (a, b) or PADK (c, d). Equal protein aliquots were 
assessed by immunoblot for anti-αII-spectrin staining of the 150-kDa SBDP and for labeling 
of a gel loading control. Calcium-induced SBDP levels were normalized to the 0 µM control 
and means ± SEM were compared to the control: *p<0.05, **p≤0.01. PADK had no effect on 
SBDP. 
8th International Scientific Forum, ISF 2017, 7-8 September 2017, UNCP, USA,   Proceedings 
47 
Concerning the calpain-mediated gephyrin fragments previously 
characterized in hippocampal membranes, calcium treatment of rat 
telencephalic samples also led to the production of a 49-kDa breakdown 
product (GnBDP49) as found in the hippocampal study, and to the production 
of a smaller 18-kDa fragment (GnBDP18) labeled by the antibodies developed 
against gephyrin’s carboxyl-terminal sequence (Fig. 4a). Comparing the two 
distinct compounds of this study, PADK at 100 μM was found to have no effect 
on the calcium-induced generation of GnBDP18 (Fig. 4b and 4c), whereas 100 
μM E64d completely blocked the 18-kDa fragment from forming (Fig. 4c).  
 
Figure 4. E64d blocks calcium-induced gephyrin breakdown. Telencephalic homogenates 
were treated without (–) or with (+) CaCl2 at 37°C for 1 h, generating gephyrin breakdown 
products of 49 (GnBDP49) and 18 kDa (GnBDP18) that were detected by immunoblot (a). 
Molecular weight markers are shown. PADK had no effect on calcium-induced GnBDP18 
formation (b) whereas E64d blocked its formation (c).  NT, not treated with CaCl2. 
 
In addition to inhibiting the GnBDP18 proteolytic cleavage product, 
E64 blocked the formation of the larger GnBDP49 fragment as well (Fig. 5a 
and 5b). The dose-dependent reduction of the 49-kDa cleavage product in 
calcium-activated samples closely corresponded with E64d’s dose-dependent 
inhibition of spectrin breakdown (Fig. 5c). Note that the calcium-induced loss 
of the protein band shown as a gel load control was also protected by E64d. 
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Figure 5. E64d reduces GnBDP49 in calcium-treated brain tissue. Telencephalic 
homogenates were treated with CaCl2 at 37°C for 1 h, generating the gephyrin fragment 
GnBDP49 detected by immunoblot (a) and the E64d inhibitory effect was determined across 
concentrations. Calcium-induced GnBDP49 levels were normalized to the 0 µM control and 
means ± SEM were compared to the control: *p<0.0182. A corresponding E64d effect was 
found for blocking calcium-induced SBDP levels (c). NT, not treated with CaCl2. 
 
Next, we tested the E64d and PADK compounds for the ability to 
protect the parent gephyrin protein, the 95-kDa isoform, from deterioration by 
calcium-induced proteolysis. In a pair of calcium-treated telencephalic 
homogenates, the brain sample with the addition of E64d exhibited a 
correspondence between blocking gephyrin fragment formation and 
protecting the parent gephyrin (see top two blot strips in Fig. 6a). As also 
indicated in the figure, the E64d inhibitor had similar abilities to 1) reduce 
gephyrin from being fragmented to GnBDP49 and other breakdown products 
and 2) reduce spectrin from being proteolyzed to the SBDP calpain cleavage 
product.  
  
8th International Scientific Forum, ISF 2017, 7-8 September 2017, UNCP, USA,   Proceedings 
49 
  
 
Figure 6. E64d protects the 95-kDa parent gephyrin from being proteolytically 
depreciated. The calcium-treated brain homogenates incubated in the absence (–) or 
presence of E64d (+) were assessed by immunoblot for both the parent gephyrin and 
GnBDP49 as well as SBDP (a). PADK- and E64d-treated samples were assessed for 
protection of calcium-induced loss of gephyrin (b). Integrated optical densities (mean 
IODs ± SEM) of gephyrin labeling were normalized to the 0 µM control for PADK 
samples (no protection) and for E64d samples that exhibited protection to levels that 
were ≥control levels (c). Dotted line: gephyrin amount in no-calcium control samples.   
  
Additional calcium-treated brain samples were incubated with 10-100 
μM PADK and showed no evidence that PADK protected the 95-kDa parent 
gephyrin, but samples treated with 10-100 μM E64d were associated with 
robust levels of protected gephyrin protein (Fig. 6b). When examining the 
effects across dosages of PADK and E64d, for evidence that they govern 
cytoskeletal decay, calcium-treated samples with different PADK 
concentrations fell well below the control gephyrin measures from samples 
without the calcium incubation (average control level noted by dotted line in 
Fig. 6c). This finding indicates that no protection of gephyrin was produced 
by PADK. In contrast, calcium-incubated samples with different E64d 
8th International Scientific Forum, ISF 2017, 7-8 September 2017, UNCP, USA,   Proceedings 
50 
concentrations exhibited amounts of parent gephyrin that approached or 
exceeded the dotted-line control level of gephyrin (Fig. 6c). Interestingly, the 
calcium-activated homogenates that were treated with 10-100 μM E64d 
exhibited much more parent gephyrin than those homogenate samples that 
were treated with 100 μM PADK. Together with results of the breakdown 
product experiments, these findings indicate that E64d protects gephyrin from 
calpain-mediated proteolytic damage.  
 
Discussion 
 For over 30 years, research programs for developing neurotherapeutics 
and other disease treatments have included cysteine protease inhibitors (see 
Wang & Yuen, 1994; Nixon, 2000; Vanderklish & Bahr, 2000; Trinchese et 
al., 2008; Saatman et al., 2010; Ono et al., 2016; Sugiyama et al., 2017). For 
protein accumulation disorders (e.g., AD, Parkinson’s disease, and 
Huntington’s disease), it is counterintuitive to use protease inhibitors that 
would block the same protein clearance pathways whose dysfunctions are part 
of pathogenic cascades (see Torres et al., 2012; Burbulla et al., 2017; Farizatto 
et al., 2017). Pathogenic protein clearance is a critical issue for AD-type 
pathology since Aβ42 and Aβ40 peptides have impaired clearing rates in the 
human disease (Mawuenyega et al., 2010). Accordingly, a growing number of 
studies has investigated agents that enhance enzymes appropriately involved 
in protein clearance. The CatB cysteine protease is one such enzyme: it is a 
lysosomal hydrolase that degrades Aβ into less amyloidogenic species 
(Mueller-Steiner et al., 2006; Butler et al., 2011; Wang et al., 2012; Cermak 
et al., 2016; Park et al., 2016) and it is neuroprotective when up-regulated, 
reducing synaptic and behavioral deficits related to AD (Mueller-Steiner et al., 
2006; Sun et al., 2008; Butler et al., 2011; Yang et al., 2011; Viswanathan et 
al., 2012). The PADK and E64d compounds compared here are both very 
weak inhibitors of the Aβ-degrading CatB, but both were found to up-regulate 
CatB levels which may explain their beneficial actions in AD mouse models 
(see Butler et al., 2011; Hook et al., 2011; Bahr et al., 2012). It is noteworthy, 
however, that the two compounds exhibited distinct actions on the active CatB 
isoform vs. the calcium-dependent cysteine protease calpain: 
  PADK up-regulated CatB-30 by 549% while causing no apparent 
change in calpain activity; 
  
  E64d  up-regulated  CatB-30  by  76%  but reduced calpain activity by 
80-90%. 
   PADK has a >7-fold effect on CatB enhancement as compared to E64d’s 
effect, as indicated by hippocampal slices after being treated with the compounds. 
PADK’s robust effect on CatB explains the improved protein clearance as part of 
its protective actions in AD mouse models, which is consistent with human 
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studies showing exercise elevates CatB levels in correlation with improved 
memory (Moon et al., 2016). E64d, on the other hand, elicits a much smaller 
enhancing effect on CatB, but this small enhancement may be part of E64d’s 
therapeutic action at concentrations that do not block the protein clearing role of 
CatB.  
 This study also indicates that PADK and E64d differ mechanistically 
in their abilities to block calpain-mediated proteolysis. PADK’s positive effect 
on CatB was found to be selective, apparently independent of any inhibitory 
effect on calpain, an enzyme linked to several neurodegenerative disorders 
including stroke, seizures, TBI, and AD (see reviews: Nixon, 2000; 
Vanderklish & Bahr 2000). E64d’s blocking of calpain-mediated cytoskeletal 
damage was observed to be many times more potent than its effect on CatB. 
Thus, PADK and E64d may provide separate yet promising therapeutic 
avenues by acting on different targets (see Fig. 7).  
 PADK increases CatB-30 levels through an interaction with the CatB 
enzyme’s active site. Such an interaction appears to occur to different degrees 
by phenolic-rich structures including PADK, the related Z-Phe-Phe-
diazomethylketone, the nonpeptidic modulator SD1002, and the natural 
phenolic compound quercetin since they were effective at up-regulating CatB-
30. In contract, the structurally distinct epoxysuccinyl peptide E64d acted 7-
fold less potently than PADK for CatB positive modulation. In addition to 
lacking phenolic motifs that may facilitate the modulation, E64d is known to 
be hydrolyzed once it readily permeates into cells, becoming a potent cysteine 
protease inhibitor with an IC50 for blocking calpain of 0.04 μM (Huang et al., 
1992). This feature of E64d likely influences its ability to up-regulate CatB 
since the better positive CatB modulators identified here are very weak 
inhibitors of cysteine proteases.   
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Figure 7. Differential pathways and therapeutic targets of PADK and E64d. PADK has 
a positive and selective effect on lysosomal CatB which likely explains its beneficial effect 
on AD-type protein accumulation pathology. E64d elicits low-level positive CatB modulation 
which may be part of its therapeutic action. In addition, evidence indicates that E64d potently 
blocks pathogenic, calpain-mediated cytoskeletal damage, and the compound is known to 
block a number of lysosomal enzymes. The singular action on calpain or the dual effect on 
calpain and the lysosomal pathway may explain E64d’s protective results. 
 
 The results suggest that E64d targets the calcium-regulated enzyme 
calpain, an enzyme that is essential to a host of cellular processes and is known 
to participate in many pathologic cascades. E64d effectively reduced 
cytoskeletal degradation linked to neuropathology, evaluated by measuring 
spectrin and gephyrin proteolysis that was shown previously to be blocked by 
selective calpain inhibitors (Kawasaki et al., 1997; Vanderklish & Bahr 2000). 
E64d and PADK exhibited disparate effects on the cytoskeletal damage in 
brain samples: 
  E64d blocked calcium-mediated spectrin and gephyrin breakdown at 
≥10 μM; 
  E64d protected the parent gephyrin from calcium-mediated 
proteolysis at ≥10 μM; 
  PADK did not block the induced cytoskeletal breakdown or protect 
the parent gephyrin. 
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 Of its different modulatory actions depicted in Figure 7, E64d’s 
negative modulation of calpain alone very likely explains its protective effects 
against neurodegenerative insults, rather than through dual inhibition of both 
calpain and a family of lysosomal cathepsins (E64d is listed as an inhibitor of 
cathepsins B, F, H, K, and L). First, selective calpain inhibitors have been 
widely reported to protect against ischemic insults and TBI (see Vanderklish 
& Bahr, 2000; Saatman et al., 2010; Ono et al., 2016). Second, E64d 
completely protected against the TBI-induced neuronal loss measured in CatB 
knockout mice (Hook et al., 2014b). Third, intracellular and hydrolyzed E64d, 
having a 0.04-μM IC50 for blocking calpain (Huang et al., 1992), is 350 times 
more potent towards calpain vs. CatB and has been shown to lower Aβ peptide 
levels and improve memory in APP transgenic mice (Hook et al., 2007, 2011, 
2014a). In comparison, the calpain inhibitor BDA-410 is 748 times more 
potent towards calpain vs. CatB and exhibited similar memory improvement 
as well as restored normal synaptic functions in AD mice (Trinchese et al., 
2008). Lastly, inhibition of cathepsins would not be a beneficial feature to add 
to a therapeutic for synaptic/cognitive protection since CatB-blocking levels 
of cysteine protease inhibitors were found to be toxic, causing the 
accumulation of APP fragments and reducing synaptic protein measures (Bahr 
et al., 1994). Similarly, E64d blocked lysosomal protein clearance leading to 
accumulating levels of the mutant huntingtin protein (Jeong et al., 2009). 
 Inhibiting calpain enzymes as a therapeutic avenue has long been a 
challenge since reducing calpain activity can i) negatively affect one of the 
many physiological roles for calpains and ii) lead to adverse side effects. Even 
with these challenges, drug discovery efforts remain active to develop calpain-
targeted strategies to treat cancer, cardiovascular diseases, drug abuse, and 
neurodegenerative disorders including latter stages of AD (see Ono et al., 
2016; Liang et al., 2017).  
 Interestingly, the E64d neuroprotectant, shown to be effective in 
London-mutant APP mice, appears to be the first compound identified that is 
both a potent calpain inhibitor and a positive modulator of the lysosomal 
pathway through CatB up-regulation. As should be noted, a cautionary study 
reported that all APP-overexpressing mice exhibit a toxic protein 
accumulation that does not occur in AD brains and that calpain activation can 
be an artifact of APP overexpression (Saito et al., 2016). Notwithstanding, 
aberrant calpain activity may play a role in AD-related oxidative stress and 
age-related disruption of proteostasis that lead to lysosomal destabilization 
(see Nixon, 2000; Yamashima, 2016). Perhaps related, calpain inhibition has 
been suggested to promote protective protein clearance through inducing the 
autophagic-lysosomal pathway (Menzies et al., 2015; Watchon et al., 2017) 
and blocking the switch from 26S to 20S proteasomes in order to enhance 
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regulated 26S proteasomal protein degradation that is essential for neuronal 
health and survival (Huang et al., 2013). Thus, a potential therapeutic with 
calpain inhibitory and lysosomal enhancement properties may elicit two 
separate avenues for proteostasis protection. CatB enhancement, in fact, has 
been shown to protect against AD-type protein accumulation pathology and 
associated synaptic compromise in a chloroquine-induced model of protein 
accumulation stress (Bendiske & Bahr, 2003; Butler et al., 2005; Rhyzikov & 
Bahr, 2008) and in models directly treated with Aβ42 (Park et al., 2016; 
Farizatto et al., 2017).  
 In summary, among the weak cysteine protease inhibitors assessed, the 
PADK compound was found to have a positive effect on CatB but did not 
appear to inhibit calpain. E64d, on the other hand, was demonstrated to be 
both a positive CatB modulator and a potent calpain inhibitor. This dual action 
suggests E64d has a unique ability to treat protein accumulation events related 
to AD. 
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